As the Director of Preclinical Pharmacology at Teva Pharmaceuticals, Ianai Fishbein plays a pivotal role in driving innovative drug discovery and development within the realm of global R&D. Leading a dynamic team of scientists, Ianai is at the forefront of developing both small molecules and...
As the Director of Preclinical Pharmacology at Teva Pharmaceuticals, Ianai Fishbein plays a pivotal role in driving innovative drug discovery and development within the realm of global R&D. Leading a dynamic team of scientists, Ianai is at the forefront of developing both small molecules and biological compounds, navigating the complexities of preclinical development with a focus on efficacy and safety. His extensive academic background, including a PhD in Neurobiology from the Weizmann Institute and a Postdoctoral fellowship at the University of California, San Francisco (UCSF), equips him with a profound understanding of the biological mechanisms underlying drug action.
Under Ianai's leadership, the team is dedicated to executing sophisticated in-vitro and in-vivo biological assays and screens, which are critical for evaluating the therapeutic potential of novel compounds across various indications. His expertise in techniques such as Western Blotting, PCR, and Fluorescence Microscopy, combined with his proficiency in animal models and molecular biology, enables the team to conduct rigorous assessments of compound efficacy and safety profiles. Ianai's commitment to fostering a collaborative environment encourages innovation and creativity, empowering his team to explore cutting-edge methodologies in drug discovery.
Key projects under Ianai's direction include the development of targeted therapies for complex diseases, where his strategic vision and scientific acumen are instrumental in translating research findings into viable therapeutic options. His role not only emphasizes the importance of scientific rigor but also highlights the necessity of cross-disciplinary collaboration in the ever-evolving landscape of pharmaceuticals. Ianai's leadership exemplifies a commitment to advancing healthcare through innovative research, ultimately aiming to improve patient outcomes on a global scale.
